These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9453943)

  • 1. [Prevention of recurrent erosive reflux esophagitis].
    Müller P; Simon B
    Fortschr Med; 1997 Oct; 115(30):46-7. PubMed ID: 9453943
    [No Abstract]   [Full Text] [Related]  

  • 2. [Long-term therapy with omeprazole: when will it finally be approved?].
    Koop H
    Leber Magen Darm; 1995 Jul; 25(4):153-4. PubMed ID: 7564865
    [No Abstract]   [Full Text] [Related]  

  • 3. [Short-term intervention in ulcer and reflux. New acid blocker halves duration of therapy].
    Einecke D
    MMW Fortschr Med; 2000 Jul; 142(26-27):50-1. PubMed ID: 10929487
    [No Abstract]   [Full Text] [Related]  

  • 4. [Maintenance therapy in reflux esophagitis].
    Katsoulis S; Fölsch UR
    Z Gastroenterol; 1997 Feb; 35(2):159-61. PubMed ID: 9163230
    [No Abstract]   [Full Text] [Related]  

  • 5. Low-dose omeprazole for erosive esophagitis.
    Epling J; Taylor H
    J Fam Pract; 1999 Feb; 48(2):93-4. PubMed ID: 10037536
    [No Abstract]   [Full Text] [Related]  

  • 6. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
    Thjodleifsson B; Beker JA; Dekkers C; Bjaaland T; Finnegan V; Humphries TJ
    Dig Dis Sci; 2000 May; 45(5):845-53. PubMed ID: 10795744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable?
    Boccia G; Manguso F; Miele E; Buonavolontà R; Staiano A
    Am J Gastroenterol; 2007 Jun; 102(6):1291-7. PubMed ID: 17319927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Generous treatment with gastric acid blockers. For patients with gastric reflux the proton pump inhibitor power is cost-effective].
    MMW Fortschr Med; 2003 Feb; 145(6):56-7. PubMed ID: 12619364
    [No Abstract]   [Full Text] [Related]  

  • 9. Increasing concerns about chronic proton pump inhibitor use.
    Svoboda AC
    J Clin Gastroenterol; 2001 Jul; 33(1):3-7. PubMed ID: 11418781
    [No Abstract]   [Full Text] [Related]  

  • 10. [A case of gastric fundic polyps during long-term treatment of reflux esophagitis with omeprazole].
    Yamamoto T; Matsumoto J; Kosaihira T; Nomoto M; Kitajima S; Arima T
    Nihon Shokakibyo Gakkai Zasshi; 2003 Apr; 100(4):421-5. PubMed ID: 12722347
    [No Abstract]   [Full Text] [Related]  

  • 11. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis.
    Lightdale CJ; Schmitt C; Hwang C; Hamelin B
    Dig Dis Sci; 2006 May; 51(5):852-7. PubMed ID: 16773434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis.
    Baldi F; Morselli-Labate AM; Cappiello R; Ghersi S;
    Am J Gastroenterol; 2002 Jun; 97(6):1357-64. PubMed ID: 12094850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis.
    Ligumsky M; Lysy J; Siguencia G; Friedlander Y
    J Clin Gastroenterol; 2001 Jul; 33(1):32-5. PubMed ID: 11418787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis.
    Earnest DL; Dorsch E; Jones J; Jennings DE; Greski-Rose PA
    Am J Gastroenterol; 1998 Feb; 93(2):238-43. PubMed ID: 9468251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group.
    Andersson T; Hassall E; Lundborg P; Shepherd R; Radke M; Marcon M; Dalväg A; Martin S; Behrens R; Koletzko S; Becker M; Drouin E; Göthberg G
    Am J Gastroenterol; 2000 Nov; 95(11):3101-6. PubMed ID: 11095324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group.
    Hassall E; Israel D; Shepherd R; Radke M; Dalväg A; Sköld B; Junghard O; Lundborg P
    J Pediatr; 2000 Dec; 137(6):800-7. PubMed ID: 11113836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis.
    Schmitt C; Lightdale CJ; Hwang C; Hamelin B
    Dig Dis Sci; 2006 May; 51(5):844-50. PubMed ID: 16642422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment interruptus: the need for withdrawal.
    Hassall E
    Am J Gastroenterol; 2007 Sep; 102(9):2108-9. PubMed ID: 17727443
    [No Abstract]   [Full Text] [Related]  

  • 19. [Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
    Dohmen W; Fuchs W
    MMW Fortschr Med; 2005 Mar; 147(9):39. PubMed ID: 15794353
    [No Abstract]   [Full Text] [Related]  

  • 20. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
    Festen HP; Schenk E; Tan G; Snel P; Nelis F
    Am J Gastroenterol; 1999 Apr; 94(4):931-6. PubMed ID: 10201459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.